Jennifer Nessel, Assistant Editor

A patient at age 65 with high blood pressure could extend their life by more than a year with intensive treatment focused on a target systolic blood pressure of less than 120 mm Hg.

Tafenoquine’s approval was the culmination of years of scientific discovery and research by experts in the field of Malariology and Infectious Disease, involving over 25 clinical trials and over 3000 participants.

The 48-week phase 4 study showed that tocilizumab was more effective than rituximab in patients with rheumatoid arthritis with low B cell levels in synovial tissue.

The Clinical Performance and Quality Measures included 6 performance measures, 6 process quality measures, and a new category of 10 structural quality measures for adults with high blood pressure.

Certain subgroups may see a greater reduction in heart failure hospitalizations and cardiovascular death with the combination of sacubitril and valsartan.

The FDA has granted approvel to Alnylam’s givosiran (Givlaari) for the treatment of adults with acute hepatic porphyria.

A recent study suggests that hyperkalemia and uncomplicated hyperglycemia in patients treated in the emergency department is commonly caused by iatrogenesis.

The study authors wanted to determine the prevalence and clinical significances of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.

Researchers in the JADE MONO-1 study investigated whether patients aged 12 years and older with moderate to severe atopic dermatitis would achieve with abrocitinib could achieve clear or almost clear skin with abrocitinib.

cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.

Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.

Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.

According to the affiliation agreement, the Institute for Safe Medication Practices will be an ECRI Institute subsidiary when the transaction closes in January, 2020.

The largest study of its kind has found that 40% of the European population carries a genetic variant that leads to antibody resistance against anti-tumor necrosis factor (TNF) drugs, infliximab and adalimumab, and lose response.

A study reveals that axial psoriatic arthritis and ankylosing spondylitis with psoriasis are different diseases with different genetics, demographics, and disease expression.

Neither vitamin D nor omega-3 fatty acid supplementation were found to significantly inhibit changes in serum creatinine and cystatin C decline over 5 years among adults with type 2 diabetes.

The injectable hormone tesamorelin was found to reduce liver fat and prevent liver fibrosis or scarring in people living with HIV, according to researchers and the National Institutes of Health and the National Institute of Allergy and Infectious Disease (NIAD).

Weight loss surgery found to cut the overall risk of developing cancers linked to obesity by 20%.

Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.

IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions.

Survivors of long-term diffuse large B-cell lymphoma found to have a higher risk of developing a second primary cancer.

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.

Although vitamin E acetate was identified in all bronchoalveolar fluid samples from patients who suffered lung injuries associated with vaping, THC was identified in 82% of the samples and nicotine was identified in 62%.

Study is the first to identify the presence of anti-citrullinated protein autoantibodies in human tear fluid as well as discover the new eye drop treatment.

In an interview with Pharmacy Times®, Claire Morton Reynolds, MBA, senior industry analyst of Nutrition Business Journal (NBJ), said that homeopathic medicine may be the industry to watch on pharmacy shelves.

The ADMIRAL trial found that gilteritinib is a significant addition to the treatments available for patients with FLT3 mutation-positive relapsed or refractory acute myeloid leukemia.

Informed by the newly released NCPA 2019 Digest, members of community pharmacy organizations elaborate on the ongoing discussion of value-based care and reimbursement for community pharmacists.

Study shows a significantly greater proportion of patients with Crohn disease who were administered ustekinumab every 8 weeks achieved a histologic response.

Study seeks to determine the prevalence and clinical significance of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.